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OBJECTIVES: The objective of this study was to estimate the
direct costs of medical care associated with the treatment of
primary open-angle glaucoma (POAG) in the United States.
METHODS: Retrospective analysis was conducted of the 2001
Medical Expenditure Panel Survey (MEPS) data. The MEPS col-
lected survey and administrative claims data from a nationally
representative sample of 33,556 respondents and from respon-
dents’ health care and insurance providers. Data extracted for
this study included demographics (patients >40 years of age),
medical conditions, and utilization of and payments for medical
care. Patients with POAG were identiﬁed using ICD-9-CM codes
and direct costs were calculated using patient and third-party
payments for POAG-related medical events by type of care 
provided (ofﬁce-based provider visits, prescription medications,
and outpatient services). Sample estimates were weighted and
projected to the population and 95% conﬁdence limits were 
calculated using the Taylor expansion method. RESULTS: The
estimated prevalence of POAG using the MEPS was 1.25%
(95% C.L. = 0.94%–1.56%) or 1,640,087 individuals. Total
direct costs of POAG were $1,788,914,417, with an average cost
of $1,091 per patient. Prescription medications accounted for
$1,042,509,011 (mean cost / prescription = $58; 95% C.L. =
$54–$63) of direct costs. Ofﬁce-based provider visits represented
$619,401,436 (mean cost / visit = $105; 95% C.L. = $96–$113)
and outpatient services represented $127,003,970 (mean cost /
patient = $316; 95% C.L. = $198–$434). CONCLUSIONS:
Using the MEPS, POAG was estimated to affect nearly 1.7
million individuals with resultant medical care costs approach-
ing $2 billion. Although prescription medications accounted for
58% of total direct costs, they had the lowest mean cost across
the types of care. It may well be that innovative drug therapies,
which are preferable to less effective alternatives, contribute to
less utilization of more costly medical care.
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OBJECTIVES: To estimate the treatment costs of glaucoma to
the California Medicaid program from 1995–2002. METHODS:
Patients with glaucoma (ICD-9 = 365.xx) were identiﬁed using
a 20% sample of the Medi-Cal administrative claims database
from January 1, 1995 to December 31, 2002. Yearly cost was
compared between glaucoma patients and controls through a
case-control match. For each patient with glaucoma, three 
Medi-Cal enrollees without glaucoma were matched based on
age and gender. In addition, expenditures were calculated for
inpatient, outpatient, pharmacy, and other medical costs during
the ﬁrst year after the initial glaucoma diagnosis. All costs were
eligibility-adjusted by the number of eligible months. RESULTS:
In total, 32,395 glaucoma patients matched a cohort of 97,185
controls. The average age was 65.5 years and 65% were female.
The average yearly costs for glaucoma patients were $4191 and
$4021 for control patients. The cost steadily increased over the
eight-year study period at a rate higher in glaucoma patients than
in the control group. For the glaucoma patients, the treatment
costs in 2002 were more than twice of controls in 1995 ($5974
vs. $2597), without adjusting for inﬂation. On average, the ﬁrst
year treatment costs after the initial diagnosis for glaucoma
patients were $4347, where $1554 (35.7%) were pharmacy
costs, $1315 (30.2%) hospitalization, $595 outpatient, and
other medical costs were $1086. Additional analysis suggested
that in year 2002, Medi-Cal incurred an incremental $116
million dollars due to glaucoma. CONCLUSIONS: The eco-
nomic burden of glaucoma to the Medi-Cal program doubled
between 1995 and 2002.
PEY8
PATIENT-REPORTED VISUAL FUNCTION IN LOW-VISION
POPULATIONS (NEI-VFQ):AN ANALYSIS WITH
COMPARISONS OF READING PERFORMANCE, CONTRAST
SENSITIVITY, SCOTOMA TESTING,AND VISUAL ACUITY
Tencer T1, Chang TS1, Fletcher DC2, Globe DR1
1University of Southern California, Los Angeles, CA, USA;
2Smith-Kettlewell Eye Research Institute, San Francisco, CA, USA
OBJECTIVES: To assess the criterion validity of a patient
reported visual function instrument (NEI-VFQ) in a cohort of
low vision patients using clinical parameters. METHODS: A
subset of the NEI-VFQ-51 items was administered to 255 low
vision patients. Contrast sensitivity (CS), visual acuity (VA),
reading acuity (RA), critical print size and maximum reading rate
were measured. Retinal visual function was evaluated and foveal
functioning assessed. The association of the NEI-VFQ subscales
with clinical parameters were assessed by Pearson’s correlation
coefﬁcients. Subscale scores between patients with stable/
unstable vision loss and a functioning/non-functioning fovea
were compared using Students T-test. Linear regression models
were used to calculate the differences in scores that corresponded
to a clinically signiﬁcant three-line loss in visual acuity.
RESULTS: Binocular VA was signiﬁcantly correlated with the
near vision (r = -0.56, p < 0.0001) and distance vision subscales
(r = -0.45, p < 0.0001). Contrast sensitivity was moderately cor-
related with near vision (r = 0.36, p < 0.001) and more strongly
correlated with distance vision (r = 0.42, p < 0.001). The
maximum reading rate was signiﬁcantly correlated with VA (r =
0.53, p < 0.0001). Patients with unstable visual loss reported a
signiﬁcantly lower mean composite score (6.0 points, p = 0.03),
expectation score (19.9 points, p < 0.0001) and social function-
ing score (7.9 points, p = 0.03) than patients with stable visual
loss. Signiﬁcant differences were found in the near (22.5 points,
p < 0.0001), distance (11.8 points, p = 0.015), social function-
ing (15.5 points, p = 0.015), and role limitations (17.0 points, p
= 0.009) subscales between patients with a functioning versus
non-functioning fovea. A three-line difference in visual acuity
was associated with a 5.8 to 10.9 point difference in the NEI-
VFQ domains. CONCLUSION: The NEI-VFQ correlated sig-
niﬁcantly with reading speed and binocular visual acuity. Foveal
functioning is signiﬁcantly associated with the near and distance
subscales, as well as reading speeds. A minimally important clin-
ical difference of three lines of VA is associated with a 5.8–10.9
difference in NEI-VFQ scores.
GI DISORDERS
PGI1
PREVALENCE AND RISK FACTORS FOR DIARRHEA AT A
LARGE TERTIARY CARE MEDICAL CENTER
Kachroo S1, Kumar N1, Graham G2, Gerard L1, Dao T2, Price M2,
Dupont H2, Garey KW1
1University of Houston, College of Pharmacy, Houston,TX, USA; 2St.
Luke’s Episcopal Health System, Houston,TX, USA
